Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

163
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
163
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

192
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
192
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

152
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
152
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

141
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
141
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

149
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
149
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

1.5K
In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
1.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A large animal model of heritable pulmonary arterial hypertension using gene-edited BMPR2 sheep.

JCI insight·2026
Same author

Racial and Ethnic Variation in Outpatient Respiratory Outcomes in Bronchopulmonary Dysplasia.

The Journal of pediatrics·2026
Same author

Echocardiographic Detection of Pulmonary Hypertension and Right Ventricular Failure in Infants with Bronchopulmonary Dysplasia: A Survey of the BPD Collaborative.

Children (Basel, Switzerland)·2026
Same author

Evolving Concepts in Pulmonary Hypertension: Implementation Challenges of the Current Guidelines and Proceedings in the US.

Chest·2026
Same author

The Role of the Cellular Communication Network Protein Family in Pulmonary Arterial Hypertension.

Pulmonary circulation·2026
Same author

A Large Animal Model of Heritable Pulmonary Arterial Hypertension Using Gene-edited <i>BMPR2</i> Sheep.

bioRxiv : the preprint server for biology·2026

相关实验视频

Updated: Jun 18, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K

儿童肺高血压的研究

Rachel T Sullivan1, Eric D Austin2

  • 1Division of Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, Monroe Carrell Jr Children's Hospital, Nashville, TN 37232-2578, USA.

Clinics in chest medicine
|July 28, 2024
PubMed
概括

儿科肺高血压 (PH) 影响儿童,与成人形式有相似之处. 治疗和护理方面的进步显著提高了PH儿童到成年后的生存率.

科学领域:

  • 儿童心脏病学 儿童心脏病学
  • 肺部病理学 肺部病理学
  • 血管生物学 血管生物学

背景情况:

  • 肺高血压 (PH) 可以发生在任何年龄,包括童年.
  • 儿科PH通常与影响肺血管系统的早期生活条件有关.
  • 所有的成人PH类型都在儿童中被观察到,根据亚型的不同患病率.

研究的目的:

  • 总结我们对儿科肺高血压的理解.
  • 突出儿童PH的治疗和生存的演变.
  • 强调专业护理和过渡计划的重要性.

主要方法:

  • 小儿肺高血压的文献综述.
  • 对儿童PH亚型的患病率和相关性的分析.
  • 对治疗进步和护理模式的评估.

主要成果:

  • 儿科PH包括所有成年PH类型,具有亚型流行率差异.
  • 早期生活因素对儿科肺血管疾病有显著的贡献.
  • 在儿科PH队列中,显而易见的是在成年期生存的改善.

结论:

关键词:
发育过程中的肺部疾病.药物 药物 药物 药物 药物儿科 儿科 儿科肺高血压是一种肺高血压.在WSPH分类中,WSPH的分类.

更多相关视频

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.2K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.3K

相关实验视频

Last Updated: Jun 18, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.2K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.3K
  • 儿科PH需要专门的,多学科的护理方法.
  • 针对PH的药物和治疗方法的进步提高了结果.
  • 成功的过渡计划对于长期的儿科PH患者管理至关重要.